Table 2 |
||
|
Drugs used to treat arthritis |
||
|
Type of drug |
Name of drug |
Use |
|
|
||
|
Drugs that affect symptoms of the disease (analgesics) |
Acetaminophen Aspirin |
Relieves pain Reduces inflammation and relieves pain |
|
Oral nonsteroidal anti-inflammatory drugs (NSAIDs) |
Diclofenac Diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin |
Reduces inflammation and relieves pain All NSAIDs treat the symptoms and decrease inflammation but do not alter the course of the disease |
|
COX-2 inhibitors |
Celecoxib, valdecoxib |
Reduces inflammation and relieves pain |
|
Narcotic/analgesics |
Propoxyphene Tramadol |
Relieves pain Relieves pain |
|
Corticosteroids |
Methylprednisolone, prednisone, injectable corticosteroids |
Suppresses inflammation in severe organ disease or life-threatening disease |
|
Disease-modifying antirheumatic drugs (DMARDs)a |
Auranofin (oral gold), cyclosporine, gold salts (injectable), hydroxychloroquine, leflunomide, methotrexate, penicillamine, sulfasalazine |
All DMARDs can slow progression of joint damage as well as gradually decrease pain and swelling |
|
Biologics |
||
|
Anti-TNF compounds |
Adalimumab, etanercept, infliximab, certolizumab, golimumab |
Suppresses inflammation and inhibit the progress of joint damage |
|
IL-1 inhibitor |
Anakinra |
Treats moderate to severe RA in people who do not respond to DMARDs |
|
B-cell-depleting agent |
Rituximab |
Treats RA unresponsive to TNF inhibitors |
|
T-cell co-stimulation antagonist |
Abatacept |
Treats RA unresponsive to DMARD therapy |
|
IL-6 antagonist |
Tocilizumab |
Treats RA unresponsive to TNF inhibitors |
|
|
||
|
COX, cyclooxygenase; DMARD, disease-modifying anti-rheumatic drug; IL, interleukin; RA, rheumatoid arthritis; TNF, tumor necrosis factor. |
||
|
Cuzzocrea Arthritis Research & Therapy 2011 13:126 doi:10.1186/ar3434 |
||